A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis
Clinical trial NCT06559150 · RECRUITING
Trial details
- NCT number
- NCT06559150
- Sponsor
- Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-09-11
- Primary completion
- 2027-09-24
- Enrollment
- 284
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.